Navigation Links
Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day
Date:10/24/2011

BROOMFIELD, Colo., Oct. 24, 2011 /PRNewswire/ -- Accera, Inc., a biotech company specializing in cognitive health, announced today the company has donated $50,000 to the Alzheimer's Foundation of America (AFA) for sponsorship of its "National Memory Screening Day" (NMSD) during National Alzheimer's Disease Awareness Month.  These funds will be used to further the AFA's efforts to educate and support individuals with Alzheimer's disease (AD) and their families, especially about the importance of early detection of memory problems.

Eric J. Hall, founding president and CEO of AFA, said, "We're grateful that despite the difficult economy, Accera continues to demonstrate its generous commitment to individuals and their families facing Alzheimer's disease now or in the future.  It's a public health crisis that requires corporate engagement."

NMSD, an annual initiative sponsored by AFA, provides free, confidential, memory screenings to individuals concerned about memory loss with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation on November 15.

Samuel Henderson, Ph.D., vice president of research and development for Accera, stated, "On behalf of the Accera team, we're happy to contribute to AFA's ongoing efforts of helping those affected by Alzheimer's and raise awareness about the options available to patients and their caregivers."  He continued, "It's our hope that through continued awareness initiatives such as NMSD, we can better educate patients and their families about this devastating disease."

About Alzheimer's disease
AD significantly impacts millions of family members and other caregivers – mentally, physically and financially.  The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week.  With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Axona®
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells.  With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.  For more information about Axona, please visit www.about-axona.com or contact a doctor who is familiar with the product.

About Accera, Inc.  
Accera, Inc. is a privately held commercial-stage cognitive health company that developed and now markets Axona in the US.  Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease.  In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients.  Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease.  Accera engages in research, development and commercialization of other clinical applications for Axona.

For more information about Accera, please visit www.accerapharma.com.Contacts:Accera, Inc.
(303) 999-3705
Bill Poncy
VP Commercial Development
bponcy@accerapharma.com

Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach

amielach@tiberend.com
or
Madeleine Desmond

mdesmond@tiberend.com
'/>"/>

SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. to Support the Alzheimers Foundation of Americas National Memory Screening Day Through On-line Awareness Effort
2. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
3. Accera, Inc. to Present at Upcoming Investor Conferences
4. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
5. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
6. Accera, Inc. Completes $35 Million Series C Financing
7. The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan
8. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
9. Vita-Tech International, Inc. Donates One Ton of Vitamins To Polio Treatment Centers in Guinea, West Africa
10. GeneGo Donates Proprietary Cytokine Pathway Maps to ISICR
11. SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):